| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(98)11293-X |
| P698 | PubMed publication ID | 10509495 |
| P50 | author | Gioacchino Leandro | Q42705700 |
| P2093 | author name string | A K Burroughs | |
| J Goulis | |||
| P2860 | cites work | Meta-analysis in clinical trials | Q27860779 |
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Serum bilirubin: a prognostic factor in primary biliary cirrhosis | Q34494336 | ||
| Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models | Q36477724 | ||
| Accuracy of staging in primary biliary cirrhosis | Q37218972 | ||
| Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis | Q38698807 | ||
| Prediction of short-term survival with an application in primary biliary cirrhosis | Q39085766 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Surrogate end points in clinical trials: are we being misled? | Q41117631 | ||
| Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study | Q42551010 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| Optimal timing of liver transplantation for primary biliary cirrhosis. | Q52240035 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| Primary biliary cirrhosis | Q68930413 | ||
| Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis | Q71035932 | ||
| Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials | Q71129744 | ||
| A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis | Q71995039 | ||
| A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid | Q72189521 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up | Q72223002 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC | Q72789964 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis | Q73186060 | ||
| Primary biliary cirrhosis: questions and promises | Q73316085 | ||
| Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
| Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis | Q74529900 | ||
| Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression | Q74645177 | ||
| Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications | Q77598543 | ||
| Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis | Q77716502 | ||
| P433 | issue | 9184 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| primary biliary cholangitis | Q1072420 | ||
| randomized controlled trial | Q1436668 | ||
| P304 | page(s) | 1053-1060 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | |
| P478 | volume | 354 |
| Q27482028 | A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C |
| Q44906209 | A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis |
| Q44825279 | A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results |
| Q34619432 | Administration of tauroursodeoxycholic acid (TUDCA) reduces apoptosis following myocardial infarction in rat. |
| Q28354314 | An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity |
| Q36036857 | Antifibrotic therapy in chronic liver disease |
| Q34269621 | Autoimmune liver disease. Current standards, future directions. |
| Q24243194 | Bile acids for viral hepatitis |
| Q28238498 | Bile acids: trying to understand their chemistry and biology with the hope of helping patients |
| Q33641759 | Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study |
| Q40479808 | Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies. |
| Q45309693 | Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial |
| Q36193470 | Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis |
| Q35020868 | Chronic cholestatic liver diseases |
| Q37182934 | Clinical features and management of primary biliary cirrhosis. |
| Q35760198 | Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis |
| Q46521938 | Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid |
| Q37317654 | Current and future anti-fibrotic therapies for chronic liver disease |
| Q35068031 | Current management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q38055205 | Current pharmacotherapy for cholestatic liver disease |
| Q34408950 | Current status of therapy in autoimmune liver disease |
| Q24245871 | D-penicillamine for primary biliary cirrhosis |
| Q34626518 | Deciphering the nuclear bile acid receptor FXR paradigm |
| Q37618589 | Diagnosis and Management of Chronic Pruritus: An Expert Consensus Review |
| Q36495172 | Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis |
| Q34687676 | Drug therapy of primary biliary diseases: classical and modern strategies. |
| Q44277493 | Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate |
| Q83200621 | Efficacy of ursodeoxycholic acid combined with Tongdan Decoction () on immunological indices and histopathological changes in primary biliary cirrhosis patients |
| Q38744215 | Emerging drugs for the treatment of Primary Biliary Cholangitis |
| Q36119487 | Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy |
| Q34769039 | Fatigue in cholestatic liver disease--a perplexing symptom |
| Q33912957 | Fenofibrate in primary biliary cirrhosis: a pilot study. |
| Q46982754 | Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom |
| Q24244255 | Glucocorticosteroids for primary biliary cirrhosis |
| Q56429943 | Guidelines for the management of primary biliary cirrhosis |
| Q35565635 | HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility |
| Q79185420 | Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis |
| Q35594405 | Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. |
| Q40271507 | Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis |
| Q44139912 | Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis |
| Q55044287 | Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. |
| Q28141076 | Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management |
| Q43865110 | Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy |
| Q35028987 | Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity |
| Q34550505 | Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials |
| Q52933260 | Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. |
| Q45250878 | Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. |
| Q79222550 | Management of primary biliary cirrhosis |
| Q35734498 | Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease |
| Q34017604 | Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets |
| Q81724957 | Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q45151761 | Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis |
| Q44277489 | Methotrexate therapy for primary biliary cirrhosis |
| Q50130002 | Modern treatment of primary biliary cholangitis |
| Q36197335 | Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. |
| Q45948727 | Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. |
| Q58803462 | Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis |
| Q46608065 | Natural history of primary biliary cirrhosis |
| Q38261577 | New therapies for primary biliary cirrhosis |
| Q45279435 | No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis |
| Q46940563 | Nuclear receptors, bile-acid detoxification, and cholestasis |
| Q38911238 | Obeticholic acid for the treatment of primary biliary cholangitis |
| Q38628470 | Obeticholic acid for the treatment of primary biliary cirrhosis |
| Q85522942 | Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis: a 2-year follow-up study |
| Q34354186 | Options for treatment of primary biliary cirrhosis |
| Q37824300 | Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature |
| Q36119475 | Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis. |
| Q37346015 | Overlap syndromes with autoimmune hepatitis in chronic cholestatic liver diseases |
| Q84129520 | Pathogenesis and treatment of pruritus |
| Q46835520 | Patients and patience: the pitfalls of primary biliary cirrhosis trials |
| Q37681567 | Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid |
| Q24672983 | Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs |
| Q34383547 | Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials |
| Q90707736 | Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases |
| Q56428272 | Primary biliary cirrhosis |
| Q56428273 | Primary biliary cirrhosis |
| Q56854243 | Primary biliary cirrhosis |
| Q84230884 | Primary biliary cirrhosis |
| Q85213554 | Primary biliary cirrhosis |
| Q38058979 | Primary biliary cirrhosis and bile acids |
| Q26853145 | Primary biliary cirrhosis and liver transplantation |
| Q35609106 | Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q34515652 | Primary biliary cirrhosis: new thoughts on pathophysiology and treatment |
| Q35573929 | Primary biliary cirrhosis: specific treatment |
| Q35573937 | Primary biliary cirrhosis: the future |
| Q44736205 | Primary biliary liver cirrhosis and overlap syndrome. Diagnosis and therapy |
| Q44617739 | Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients |
| Q41871213 | Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis |
| Q34204223 | Quality of reporting of meta-analyses: the QUOROM statement. Will it help? |
| Q34516425 | Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis |
| Q36574505 | Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management. |
| Q33730935 | Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant |
| Q38974002 | Reversal of liver cirrhosis: current evidence and expectations |
| Q38174167 | Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q35030826 | Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? |
| Q42363647 | Risk of liver disease in methotrexate treated patients |
| Q38937793 | Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model |
| Q45074381 | Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment |
| Q43707876 | T cell repertoire in primary biliary cirrhosis: a common T cell clone and repertoire change after treatment |
| Q43734578 | Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. |
| Q34557669 | The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. |
| Q52624982 | The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. |
| Q34343494 | The farnesoid X receptor: a novel drug target? |
| Q34182672 | Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q34398020 | Treatment of primary biliary cirrhosis |
| Q43967448 | Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis |
| Q33873354 | URSO-panacea or placebo? |
| Q43561664 | Ursodeooxycholic acid for primary biliary cirrhosis |
| Q34330984 | Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. |
| Q44671802 | Ursodeoxycholic acid and histological progression in primary biliary cirrhosis |
| Q36801651 | Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses |
| Q73497916 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q24202184 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q24241945 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q44110703 | Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial |
| Q43659683 | Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future? |
| Q43623767 | Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future |
| Q44487653 | Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression |
| Q42551875 | Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy |
| Q28377666 | Ursodeoxycholic acid therapy in hepatobiliary disease |
| Q33866782 | Ursodeoxycholic acid treatment of vanishing bile duct syndromes |
| Q37012207 | Ursodeoxycholic acid: Mechanism of action and novel clinical applications |
| Q34515643 | Use of ursodeoxycholic acid in patients with liver disease |
| Q53806050 | Yinzhihuang attenuates ANIT-induced intrahepatic cholestasis in rats through upregulation of Mrp2 and Bsep expressions. |
| Q77784964 | [New therapeutic strategies in liver fibrosis: pathogenic basis] |
Search more.